Novartis forms Mereo as UK biotech spin-off
July 29, 2015Research and Development Mereo, Novartis, biotech, rare diseases
Novartis has formed a new UK biotech company by selling three investigational drugs in exchange for shares in the new …
Cambridge collaboration to boost precision medicine research
July 29, 2015Research and Development Brabaham Institute, Cambridge, R&D, collaboration
A new consortium has been launched to act as a ‘match-making’ service between pharma companies and R&D researchers to develop …
Judge rules pharma has ‘ethical’ transparency obligation – reaction
July 29, 2015Research and Development Ben Goldacre, Richmond Pharmacology, alltrials, clinical trials, health research authority, hra, sense about science, transparency
Both sides of a bitterly contested legal battle over a major part of the industry’s transparency drive have reacted to …
Judge backs HRA in transparency legal case
July 28, 2015Research and Development EU Clinical Trial Regulation, Richmond Pharmacology, alltrials, clinical trial regulation, clinical trials, health research authority, sense about science, transparency
A judge has ruled that there are likely to be no legal grounds to block the Health Research Authority’s plans …
Lupin buys Gavis to gain first US manufacturing site
July 28, 2015Manufacturing and Production Gavis, Lupin, manufacturing, production
Indian drug manufacturer Lupin is expanding to the US by purchasing Gavis pharma for $880 million, in a major boost …
Sanofi and Regeneron in immuno-oncology push
July 28, 2015Manufacturing and Production, Research and Development Cancer, PD-1 inhibitors, Regeneron, Sanofi, collaboration, immuno-oncology, pd-1
Pharma giants Sanofi and Regeneron are extending the partnership that brought new heart drug Praluent to the market, with a …
Rising to meet the infectious disease challenge
July 27, 2015Manufacturing and Production, Research and Development, Sales and Marketing Antibiotics, R&D, antibiotic resistance, infectious disease
Antibiotic-resistant infections gather more headlines than most other infectious disease topics, and have typically been seen as a neglected area …
FDA and EMA approve heart drug Praluent
July 27, 2015Sales and Marketing EMA, FDA, PCSK9, Regeneron, Sanofi, high cholesterol, praluent
The FDA and the EMA have both approved Sanofi and Regeneron’s new high cholesterol drug Praluent. Regulators on both sides …
Novartis Foundation confirms Dr Joerg Reinhard as new chairman
July 27, 2015Manufacturing and Production, Medical Communications Dr Joerg Reinhardt, Novartis
The Novartis Foundation has confirmed several new members of its board of trustees, including a new chairman in Dr Joerg …
Teva to switch generics focus to Allergan
July 27, 2015Sales and Marketing Allergan, Teva, generics, mergers and acquisitions, pharma mergers and acquisitions
Teva is in negotiations to buy Allergan’s generics division for upwards of $40 billion, according to reports. The generics firm …
FDA approves Novartis drug Odomzo
July 27, 2015Sales and Marketing Novartis, Odomzo, basal cell carcinoma, skin cancer
The FDA has given the Swiss firm the go-ahead to market its drug for skin cancer. Odomzo (sonidegib, formerly LDE225) …
EMA backs GSK’s malaria vaccine for use in Africa
July 24, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CHMP, Committee for Medicinal Products for Human USE, EMA, European Medicines Agency, GSK, WHO, malaria, world health organization
GSK has taken a significant step forward toward being the first company to bring a malaria vaccine to market, after …
EMA in push for more paediatric drug trials
July 24, 2015Medical Communications, Research and Development EMA, European Medicines Agency, clinical trials, drug development, paediatrics
The European Medicines Agency has relaxed some of its rules around the development of drugs in children, in order to …
European Commission approves Merck’s Keytruda for melanoma drug
July 23, 2015Sales and Marketing
The European Commission has approved Merck’s Keytruda (pembrolizumab) as a skin cancer treatment. Keytruda, the company’s successful anti-PD-L1 therapy and …
Cancer and immunology drugs drive strong Roche sales performance
July 23, 2015Sales and Marketing Roche, Severin Schwan, financials
Sales at Roche rose 6% in the first half of 2015, buoyed by “significant growth of sales and immunology medicines”, …
Lilly, Biogen and Roche debut Alzheimer’s disease drug results
July 22, 2015Research and Development Alzheimer's, Alzheimer's disease, Biogen, Conference, Eli Lilly, Roche, lilly
Big pharma companies have posted mixed results in trials of several potential new treatments for Alzheimer’s disease. But the results, …
BMS halts Opdivo kidney cancer trial early
July 22, 2015Research and Development BMS, Bristol-Myers Squibb, European Commission, Kidney cancer, opdivo, renal cell carcinoma
Bristol-Myers Squibb has stopped its Phase III study of its immunotherapy drug Opdivo in people with kidney cancer early after …
Cancer Drugs Fund assessment to be handed over to NICE
July 22, 2015Medical Communications, Research and Development CDF, Cancer, Cancer Drugs Fund, NHS, NHS England, NHSE, NICE, cost effectiveness, cost-effectiveness
NICE will oversee the evaluation of Cancer Drugs Fund treatments in future, under new plans due for consultation by NHS …
New ABPI executive director appointed
July 21, 2015Manufacturing and Production, Research and Development, Sales and Marketing ABPI, Richard Corbett
The UK pharma trade body the ABPI has appointed Richard Corbett as its new executive director of commercial. Corbett will …
Parliamentary launch for UK life sciences group
July 21, 2015Manufacturing and Production, Research and Development All Party Parliamentary Group on Life Sciences, Kit Malthouse, george freeman, government, lobbying, parliament
A Parliamentary body has been created to highlight the contribution the life sciences sector makes to the economy, and boost …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
